natgillin/translations-raw huggingface dataset:
Hvis noget af ovenstående gælder for Dem (eller De ikke er sikker), skal De tale med lægen eller apotekspersonalet før De tager Lacosamide Accord. 
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Lacosamide Accord.
Unge og børn på 50 kg eller derover og voksne 
Adolescents and children weighing 50 kg or more, and adults
Pakninger med 14 x 1 eller 56 x 1 tablet i perforeret enkeltdosisblister 
Packs of 14 x 1 or 56 x 1 tablet in perforated unit dose blisters Not all pack sizes may be marketed.
Hos pædiatriske patienter, der vejer 50 kg eller derover og hos voksne patientpopulationer med let til moderat nedsat nyrefunktion kan en støddosis på 200 mg overvejes, dog bør yderligere dosistitrering (>200 mg/dag) ske med forsigtighed. 
In paediatric patients weighing 50 kg or more and in adult patients with mild or moderate renal impairment a loading dose of 200 mg may be considered, but further dose titration (> 200 mg daily) should be performed with caution.
Titrering (trinvise dosisjustering) 
Titration (incremental steps)
• Søvnighed, træthed, svaghed (asteni) 
Sleepiness, tiredness, or weakness (asthenia);
Det skal De vide, før De begynder at tage Lacosamide Accord Sådan skal De tage Lacosamide Accord Bivirkninger 
What Lacosamide Accord is and what it is used for What you need to know before you take Lacosamide Accord How to take Lacosamide Accord Possible side effects
Lægen vil ordinere det Lacosamide Accord produkt, der passer bedst til barnet. 
The doctor will prescribe the formulation that is best suited to them.
Unge og børn på 50 kg eller derover og voksne Som monoterapi 
Adolescents and children weighing 50 kg or more, and adults Monotherapy
I nedenstående tabel opsummeres den anbefalede dosering ved monoterapi til børn og unge, der vejer mindre end 50 kg. 
The following table summarises the recommended posology in monotherapy for children and adolescents weighing less than 50 kg.
50 mg tablet: rød jernoxid (E172), sort jernoxid (E172), indigocarmin aluminium lake (E132) 100 mg tablet: gul jernoxid (E172) 
50 mg tablet: Iron oxide red (E172), iron oxide black (E172), indigo carmine aluminum lake (E132) 100 mg tablet: Iron oxide yellow (E172)
Titandioxid (E171) Rød jernoxid (E172) Sort jernoxid (E172) Indigokarmin aluminium lake (E132) Lecithin (soja) 
Titanium dioxide (E171) Iron oxide red (E172) Iron oxide black (E172) Indigo carmine aluminum lake (E132) Lecithin (soya)
Lacosamide Accord 100 mg filmovertrukne tabletter EU/1/17/1230/005-008 
Lacosamide Accord 100 mg film coated tablets: EU/1/17/1230/005-008
10,6 % af patienterne i lacosamid-armen seponerede behandlingen på grund af bivirkninger mod 15,6 % af patienterne i carbamazepin CRarmen. 
The discontinuation rate due to adverse reactions was 10.6 % for patients treated with lacosamide and 15.6 % for patients treated with carbamazepine CR.
Lacosamide Accord 50 mg filmovertrukne tabletter EU/1/17/1230/001-004 
Lacosamide Accord 50 mg film coated tablets: EU/1/17/1230/001-004
Lacosamide Accord 150 mg filmovertrukne tabletter EU/1/17/1230/009-012 
Lacosamide Accord 150 mg film coated tablets: EU/1/17/1230/009-012
• Nedsat følelse eller følsomhed, svært ved at formulere ord, opmærksomhedsforstyrrelser 
Decreased feeling or sensitivity, difficulty in articulating words, disturbance in attention; Noise in the ear such as buzzing, ringing or whistling;
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KUN BEHANDLINGSSTARTPAKKE Indre karton 
TREATMENT INITIATION PACK ONLY Intermediate Carton
• æsken mærket ‘Uge 4' indeholder 14 tabletter á 200 mg. 
the package marked ‘Week 3' contains 14 tablets of 150 mg, the package marked ‘Week 4' contains 14 tablets of 200 mg .
150 mg tablet: rød jernoxid (E172), sort jernoxid (E172), gul jernoxid (E172) 200 mg tablet: indigocarmin aluminium lake (E132) 
150 mg tablet: Iron oxide red (E172), iron oxide black (E172), iron oxide yellow (E172) 200 mg tablet: Indigo carmine aluminum lake (E132)
• En alvorlig hudreaktion, som kan omfatte høj temperatur og andre influenzalignende symptomer, udslæt i ansigtet, udbredt udslæt, hævede kirtler (forstørrede lymfeknuder). 
Blood tests may show a severe decrease in a specific class of white blood cells (agranulocytosis); A serious skin reaction which may include a high temperature and other flu-like symptoms, a rash on the face, extended rash, swollen glands (enlarged lymph nodes).
Hos pædiatriske patienter med alvorlig nedsat nyrefunktion (CLCR ≤ 30 ml/min), der vejer mindre end 50 kg og hos patienter med nyresygdom i slutstadiet, anbefales en reduktion på 25 % af den maksimale dosis. 
In paediatric patients weighing less than 50 kg with severe renal impairment (CLCR ≤ 30 ml/min) and in those with end-stage renal disease, a reduction of 25 % of the maximum dose is recommended.
Psykotiske forstyrrelser(1) Selvmordsforsøg(1) 
Aggression Agitation(1) Euphoric mood(1) Psychotic disorder(1) Suicide attempt (1)
• hvis De er allergisk over for lacosamid eller et af de øvrige indholdsstoffer i Lacosamide 
Do not take Lacosamide Accord if you are allergic to lacosamide, or any of the other ingredients of this medicine (listed in section 6).
Graviditet og amning Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, 
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Ikke almindelige: kan påvirke op til 1 ud af 100 børn 
Uncommon: may affect up to 1 in 100 children
200 mg (1 Lacosamide Accordtablet 200 mg) 
200 mg (1 tablet Lacosamide Accord 200 mg)
Lacosamide Accord 200 mg er blå, ovale filmovertrukne tabletter, ca. 16,4 x 7,6 mm, præget med ‘L' på den ene side og ‘200' på den anden. 
Lacosamide Accord 200 mg are blue, oval, approximately 16.4 x 7.6 mm, coated tablets, debossed “L” on one side and “200” on other side.
150 mg (1 Lacosamide Accordtablet 150 mg) 
150 mg (1 tablet Lacosamide Accord 150 mg)
50 mg (1 Lacosamide Accordtablet 50 mg) 
50 mg (1 tablet Lacosamide Accord 50 mg)
KUN BEHANDLINGSSTARTPAKKE MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP Blisteretikette - uge 2 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS TREATMENT INITIATION PACK ONLY Blister label - week 2
Lacosamide Accord 100 mg er mørkegule, ovale filmovertrukne tabletter, ca. 13,0 x 6,0 mm, præget med ‘L' på den ene side og ‘100' på den anden. 
Lacosamide Accord 100 mg are dark yellow, oval, approximately 13.0 x 6.0 mm, coated tablets, debossed “L” on one side and “100” on other side.
100 mg (1 Lacosamide Accordtablet 100 mg) 
100 mg (1 tablet Lacosamide Accord 100 mg)
Lacosamide Accord 150 mg laksefarvede, ovale filmovertrukne tabletter, ca. 15,0 x 6,9 mm, præget med ‘L' på den ene side og ‘150' på den anden. 
Lacosamide Accord 150 mg are salmon, oval, approximately 15.0 x 6.9 mm, coated tablets, debossed “L” on one side and “150” on other side.
Bivirkninger 
Symptoms
En 200 mg Lacosamide Accord-tablet indeholder 200 mg lacosamid. 
One tablet of Lacosamide Accord 200 mg contains 200 mg lacosamide.
Titandioxid (E171) Lecithin (soja) Rød jernoxid (E172) Sort jernoxid (E172) Gul jernoxid (E172) 
Titanium dioxide (E171) Lecithin (soya) Iron oxide red (E172) Iron oxide black (E172) Iron oxide yellow (E172)
Hvordan Lacosamide Accord tages 
How to take Lacosamide Accord
En 100 mg Lacosamide Accord-tablet indeholder 100 mg lacosamid. 
One tablet of Lacosamide Accord 100 mg contains 100 mg lacosamide.
Lacosamide Accord 50 mg er lyserøde, ovale filmovertrukne tabletter, ca. 10,3 x 4,8 mm, præget med ‘L' på den ene side og ‘50' på den anden. 
What Lacosamide Accord looks like and contents of the pack Lacosamide Accord 50 mg are pink, oval, approximately 10.3 x 4.8 mm, coated tablets, debossed “L” on one side and “50” on other side.
En 50 mg Lacosamide Accord-tablet indeholder 50 mg lacosamid. 
One tablet of Lacosamide Accord 50 mg contains 50 mg lacosamide.
En 150 mg Lacosamide Accord-tablet indeholder 150 mg lacosamid. 
One tablet of Lacosamide Accord 150 mg contains 150 mg lacosamide.
Lacosamide Accord 200 mg 1 filmovertrukket tablet indeholder 200 mg lacosamid. 
Lacosamide Accord 200 mg 1 film-coated tablet contains 200 mg lacosamide.
Børn og unge, der vejer mindre end 50 kg 
Adolescents and children weighing 50 kg or more
Hver filmovertrukket tablet indeholder 200 mg lacosamid. 
Each film-coated tablet contains 200 mg lacosamide.
• Anfald (krampeanfald), hjerteslagsproblemer, såsom langsom, hurtig eller uregelmæssig puls, 
• fits (seizures), heart beat problems such as a slow, fast or irregular heart beat , coma or a fall in blood pressure with rapid heartbeat and sweating.
• Svimmelhed 
• dizziness;
Titandioxid (E171) Lecithin (soja) Gul jernoxid (E172) 
Titanium dioxide (E171) Lecithin (soya) Iron oxide yellow (E172)
Fortæl det især til lægen eller apotekspersonalet, hvis De tager nogen af følgende lægemidler, der påvirker Deres hjerte. 
In particular, tell your doctor or pharmacist if you are taking any of the following medicines that affect your heart - this is because Lacosamide Accord can also affect your heart:
• Følelse af svimmelhed eller sygdomsfornemmelse (kvalme) 
Feeling dizzy or sick (nausea);
Lacosamide Accord 150 mg 1 filmovertrukket tablet indeholder 150 mg lacosamid. 
Lacosamide Accord 150 mg 1 film-coated tablet contains 150 mg lacosamide.
Lacosamide Accord 100 mg 1 filmovertrukket tablet indeholder 100 mg lacosamid. 
Lacosamide Accord 100 mg 1 film-coated tablet contains 100 mg lacosamide.
• Unormalt hurtig puls (ventrikulær takyarytmi) 
Not known: frequency cannot be estimated from available data Abnormal rapid heartbeat (ventricular tachyarrhythmia);
Lacosamide Accord 200 mg filmovertrukne tabletter En filmovertrukket tablet indeholder 200 mg lacosamid. 
Lacosamide Accord 200 mg film-coated tablets One film-coated tablet contains 200 mg lacosamide.
Lacosamide Accord 50 mg Lacosamide Accord 100 mg Lacosamide Accord 150 mg Lacosamide Accord 200 mg filmovertrukne tabletter lacosamid 
Lacosamide Accord 50 mg Lacosamide Accord 100 mg Lacosamide Accord 150 mg Lacosamide Accord 200 mg film-coated tablets lacosamide
Op til 400 mg/dag 
100 mg/day
Lacosamide Accord 200 mg filmovertrukne tabletter lacosamid 
Lacosamide Accord 200 mg film-coated tablets lacosamide
Lacosamide Accord 200 mg filmovertrukne tabletter 
Lacosamide Accord 200 mg film-coated tablets
Lacosamide Accord 150 mg filmovertrukne tabletter En filmovertrukket tablet indeholder 150 mg lacosamid. 
Lacosamide Accord 150 mg film-coated tablets One film-coated tablet contains 150 mg lacosamide.
Hver filmovertrukket tablet indeholder 100 mg lacosamid. 
Each film-coated tablet contains 100 mg lacosamide.
Lacosamide Accord 100 mg filmovertrukne tabletter En filmovertrukket tablet indeholder 100 mg lacosamid. 
Lacosamide Accord 100 mg film-coated tablets One film-coated tablet contains 100 mg lacosamide.
Hver filmovertrukket tablet indeholder 50 mg lacosamid. 
Each film-coated tablet contains 50 mg lacosamide.
Lacosamide Accord 150 mg filmovertrukne tabletter 
Lacosamide Accord 150 mg film-coated tablets
Lacosamide Accord 50 mg filmovertrukne tabletter lacosamid 
Lacosamide Accord 50 mg film-coated tablets lacosamide
Hver filmovertrukket tablet indeholder 150 mg lacosamid. 
Each film-coated tablet contains 150 mg lacosamide.
Lacosamide Accord 50 mg filmovertrukne tabletter 
Lacosamide Accord 50 mg film-coated tablets
Lacosamide Accord 100 mg filmovertrukne tabletter lacosamid 
Lacosamide Accord 100 mg film-coated tablets lacosamide
Lacosamide Accord 100 mg filmovertrukne tabletter 
Lacosamide Accord 100 mg film-coated tablets
Lacosamide Accord 150 mg filmovertrukne tabletter lacosamid 
Lacosamide Accord 150 mg film-coated tablets lacosamide
LÆGEMIDLETS NAVN Lacosamide Accord 50 mg filmovertrukne tabletter lacosamid 
NAME OF THE MEDICINAL PRODUCT Lacosamide Accord 50 mg film-coated tablets lacosamide
Lacosamide Accord 50 mg filmovertrukne tabletter Lacosamide Accord 100 mg filmovertrukne tabletter Lacosamide Accord 150 mg filmovertrukne tabletter Lacosamide Accord 200 mg filmovertrukne tabletter 
Lacosamide Accord 50 mg film-coated tablets Lacosamide Accord 100 mg film-coated tablets Lacosamide Accord 150 mg film-coated tablets Lacosamide Accord 200 mg film-coated tablets lacosamide
LÆGEMIDLETS NAVN Lacosamide Accord 200 mg filmovertrukne tabletter lacosamid 
NAME OF THE MEDICINAL PRODUCT Lacosamide Accord 200 mg film-coated tablets lacosamide
KUN BEHANDLINGSSTARTPAKKE Blisteretikette - uge 4 
Blister label - week 4
LÆGEMIDLETS NAVN Lacosamide Accord 150 mg filmovertrukne tabletter lacosamid 
NAME OF THE MEDICINAL PRODUCT Lacosamide Accord 150 mg film-coated tablets lacosamide
• æsken mærket ‘Uge 1' indeholder 14 tabletter á 50 mg, 
The treatment initiation pack contains 56 film-coated tablets in 4 packages: the package marked ‘Week 1'contains 14 tablets of 50 mg, the package marked ‘Week 2' contains 14 tablets of 100 mg,
LÆGEMIDLETS NAVN Lacosamide Accord 100 mg filmovertrukne tabletter lacosamid 
NAME OF THE MEDICINAL PRODUCT Lacosamide Accord 100 mg film-coated tablets lacosamide
(1) Bivirkninger rapporteret efter markedsføring. 
Fall Skin laceration Contusion (1) Adverse reactions reported in post marketing experience.
Lacosamide Accord 50 mg filmovertrukne tabletter En filmovertrukket tablet indeholder 50 mg lacosamid. 
Lacosamide Accord 50 mg 1 film-coated tablet contains 50 mg lacosamide.
Brug af anden medicin sammen med Lacosamide Accord Fortæl det altid til lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig. 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Baseret på data fra voksne bør en reduktion på 25 % af den maksimale dosis anvendes til pædiatriske patienter med mild til moderat nedsat leverfunktion, som vejer mindre end 50 kg. Lacosamids farmakokinetik er ikke blevet undersøgt hos patienter med alvorligt nedsat leverfunktion (se pkt. 
Based on data in adults, in paediatric patients weighing less than 50 kg with mild to moderate hepatic impairment, a reduction of 25 % of the maximum dose should be applied.
Udslæt(1) 
Rash(1)
Gangforstyrrelse Asteni 
Renal impairment
Svimmelhed 
Paraesthesia
Lacosamide Accord 50 mg filmovertrukne tabletter Lyserøde, ovale filmovertrukne tabletter, ca. 10,3 x 4,8 mm, præget med ‘L' på den ene side og ‘50' på den anden. 
Pink, oval, approximately 10.3 x 4.8 mm, coated tablets, debossed “L” on one side and “50” on other side.
P-piller 
Tablet core
• Besvimelse 
Discontinuation
EU/1/17/1230/013-016 EU/1/17/1230/023-024 
EU/1/17/1230/023-024
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP 
TREATMENT INITIATION PACK ONLY MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Gangforstyrrelse Asteni reaktioner på administrationsstedet 
Tabulated list of adverse reactions
--P1 PLevende gEP-P tkP-P dobbelt-gen deleteret Bovin Herpesvirus type 1 (BoHV-1), stamme CEDDEL: 10P6.3P - 10P7.3P CCIDR50 R(2 ml) (gE: deleteret glycoprotein E, tk: deleteret thymidin kinase, CCID: infektions dosis i cellekultur) 
--P1 Live gEP-P tkP-P double-gene deleted Bovine Herpes Virus type 1 (BoHV-1), strain CEDDEL: 10P6.3P - 10P7.3P CCIDR50 Rper 2 ml (gEP-P: deleted glycoprotein E; tkP-P: deleted thymidine kinase; CCID: cell culture infectious dose)
Solvens: hætteglas (type I glasflaske eller PET) 
Lyophilisate: bottle (type I glass); solvent: bottle (type I glass or PET)
Lyofilisat: 1 hætteglas solvens: 1 hætteglas 
Solvent: 1 bottle
Dette sammendrag blev sidst ajourført i marts 2015. 
This summary was last updated in March 2015.
Hvis dyret efterfølgende udsættes for disse infektioner, vil immunsystemet reagere hurtigere. 
In the future, if the animals are exposed to these infections the immune system will be able to respond more quickly.
Den smitter typisk gennem bid fra smittede dyr. 
It is typically transmitted through bites of infected animals.
Effektiviteten blev bedømt på antistofniveauet før og efter vaccinationen. 
The measure of effectiveness was levels of antibodies before and after vaccination.
I situationer, hvor hvalpene forventes at arve meget høje antistofkoncentrationer fra tæven, bør vaccinationsforløbet planlægges derefter. 
In situations where puppies are expected to inherit very high antibody levels from the bitch the vaccination protocol should be planned accordingly.
Vacciner virker ved at »lære« organismens naturlige forsvar, immunsystemet, hvordan det skal forsvare organismen mod en sygdom. 
Vaccines work by ‘teaching' the immune system (the body's natural defences) how to defend itself against a disease.
For parvovirus havde 73-100 % af hundene beskyttende antistofniveau, for parainfluenzavirus 73-97 %, for leptospira 59-96 % og for rabiesvirus 86-100 %. 
The percentage of dogs with protective levels of antibodies for parvovirus ranged from 73 to 100%, for parainfluenza virus 73 to 97%, for leptospira 59 to 96% and for rabies virus 86 to 100%.
Hvalpe reagerede undertiden mindre kraftigt end voksne hunde på grund af antistoffer, de havde arvet fra moderen. 
Responses in puppies were lower than adult dogs in some cases, because of antibodies inherited from their mothers.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Versican Plus DHPPi/L4R den 7. maj 2014. 
The European Commission granted a marketing authorisation valid throughout the European Union, for Versican Plus DHPPi/L4R on 7 May 2014.
Benefit/risk-forholdet fremgår af den videnskabelige drøftelse i denne EPAR. 
The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Vaccinen gives til hvalpe i alderen 8-9 uger ved en indsprøjtning under huden og gentages én gang, når hvalpene er 12 uger gamle. 
The vaccine is given to puppies from eight to nine weeks of age as an injection, under the skin, and repeated once the puppies reach twelve weeks of age.
Virkningen blev målt på de kliniske symptomer, kropstemperaturen og niveauet af antistoffer. 
The measures of effectiveness were clinical signs, body temperature and level of antibodies.
Den hyppigste bivirkning (ses hos mere end én ud af 100 hunde) ved Versican Plus DHPPi/L4R er kortvarig hævelse på indtil 5 cm, der kan forekomme på injektionsstedet efter vaccinationen. 
The most common side effect (seen in more than 1 in 100 dogs) with Versican Plus DHPPi/L4R is a short lived swelling of up to 5 cm which may occur at the injection site after vaccination.
Effektiviteten af Versican Plus DHPPi/L4R blev oprindelig undersøgt i en feltundersøgelse med 129 hunde. 
The effectiveness of Versican Plus DHPPi/L4R was initially investigated in a field study involving 129 dogs.
Udvalget for Lægemidler til Dyr (CVMP) konkluderede, at fordelene ved Versican Plus DHPPi/L4R opvejer risiciene til de godkendte anvendelser, og anbefalede udstedelse af en markedsføringstilladelse for Versican Plus DHPPi/L4R. 
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Versican Plus DHPPi/L4R exceed the risks for the approved indications and recommended that Versican Plus DHPPi/L4R be given a marketing authorisation.
Når Versican Plus DHPPi/L4R gives til hunde, registrerer dyrenes immunsystem virusserne og bakterierne som »fremmede« og reagerer ved at danne antistoffer mod dem. 
When Versican Plus DHPPi/L4R is given to dogs the animals' immune system recognises the viruses and bacteria as ‘foreign' and makes antibodies against them.
I disse undersøgelser blev hundene vaccineret to gange med tre ugers mellemrum og blev udsat for hundesygevirus, hundeadenovirus og hundeparvovirus tre år efter den anden vaccination. 
In these studies dogs were vaccinated twice with a three week interval and were challenged with canine distemper virus, canine adenovirus and canine parvovirus three years after the second vaccination.
Der blev efterfølgende gennemført laboratorieundersøgelser med henblik på at bestemme varigheden af beskyttelse mod hundesyge, hundeadenovirus (type 1 og 2) og parvovirus. 
Laboratory studies were conducted subsequently to determine the period of protection against distemper, canine adenovirus (type 1 and 2) and parvovirus.
Versican Plus DHPPi/L4R er en vaccine. 
Versican Plus DHPPi/L4R is a vaccine.
• - hundeparainfluenzavirus, der er årsag til kennelhoste 
• canine parainfluenza virus, the cause of kennel cough;
Versican Plus DHPPi/L4R er en vaccine, der indeholder levende, svækket hundesygevirus, hundeadenovirus type 2, hundeparvovirus type 2b og hundeparainfluenzavirus type 2 samt dræbte (inaktiverede) stammer af Leptospira-bakterier og rabiesvirus. 
Versican Plus DHPPi/L4R is a veterinary vaccine that contains live attenuated (weakened) canine distemper virus, canine adenovirus type 2, canine parvovirus type 2b and canine parainfluenza virus type 2 as well as inactivated (killed) strains of Leptospira bacteria and rabies virus.
• - rabies, hundegalskab, en virussygdom, der kan overføres til mennesker (en zoonose) og angriber centralnervesystemet (hjerne og rygmarv) med døden til følge. 
• rabies, a viral zoonotic (communicable to man) disease that affects the central nervous system (brain and spinal cord), leading to death.
Derved er de beskyttet mod hundesyge, adenovirus, parvovirose, kennelhoste, leptospirose og rabies. 
This will help protect them against distemper, adenovirus, parvovirosis, kennel cough, leptospirosis and rabies.
Feltundersøgelsen viste, at vaccination med Versican Plus DHPPi/L4R hos alle hundene gav tilstrækkelig antistofkoncentration til at beskytte mod hundesygevirus og hundeadenovirus. 
The field study showed that vaccination with Versican Plus DHPPi/L4R resulted in levels of antibodies that were sufficient to protect against canine distemper virus and canine adenovirus in all dogs.
Der revaccineres en gang om året mod parainfluenzavirus, leptospirose og rabies. 
Annual revaccination is required for protection against parainfluenza virus, leptospirosis and rabies.
Versican Plus DHPPi/L4R fås som en frysetørret pellet (et lyofilisat) med opløsningsvæske (solvens) og gives ved indsprøjtning. 
Versican Plus DHPPi/L4R is available as a lyophilisate (freeze-dried pellet) with solvent for injection.
Revaccination er nødvendig en gang hvert tredje år med en enkelt dosis af Versican Plus DHPPi/L4R mod hundesyge, hundeadenovirus (type 1 og 2) og hundeparvovirus. 
For revaccination, a single dose of Versican Plus DHPPi/L4R is required every three years for distemper, canine adenovirus (type 1 and 2) and parvovirus.
Versican Plus DHPPi/L4R anvendes til at vaccinere hunde mod: 
Versican Plus DHPPI/L4R is used to protect dogs against:
• - hundesyge, en smitsom sygdom, der på engelsk også kaldes hard pad disease, fordi hundene kan få fortykket hud på trædepuderne foruden løbende snude, hoste, feber, opkastning og diarré, 
• canine distemper, an infectious disease which is sometimes called hard pad since dogs can develop thickening of the skin on the foot pads, as well as runny nose, cough, fever, vomiting and diarrhoea, excessive salivation and in some cases fits;
• - leptospirose, en bakteriesygdom, der kan overføres via inficeret urin og medføre blødning, leverbetændelse og gulsot eller nyrebetændelse 
• leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding, hepatitis (inflammation of the liver) and jaundice or nephritis (kidney inflammation);
• - hundeadenovirus, der forårsager akut leverbetændelse, eventuelt med gulsot af hud og øjne 
• canine adenovirus, which causes an acute liver infection that may produce signs of jaundice (yellowing of the skin and eyes);
Laboratorieundersøgelserne viste, at beskyttelsesvarigheden var tre år for hundesyge, hundeadenovirus og hundeparvovirus. 
The laboratory studies showed the period of protection to be three years for canine distemper, canine adenovirus and canine parvovirus.
• - hundeparvovirus, der hos hvalpe kan medføre svær sygdom med sløvhed, feber, opkastning og blodig diarré 
• canine parvovirus disease, an infection that may severely affect puppies, resulting in lethargy, fever, vomiting and bloody diarrhoea;